Novel application of 4-carbamoyl-1- b -d-ribofuranosyl imidazolium-5-olate
CA 2042752 A1 · Owner: Saida, Takahiko · Inventors: Saida, Kyoko; Saida, Takahiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A composition for the treatment or prevention of multiple sclerosis is disclosed. It comprises mizoribine (4-carbamoyl-1-.beta.-D-ribofuranosyl imidazolium-5-olate) as the effective component. It is a safe drug exhibiting a, minimal degree of side-effects and thus can be administered, over a long period of time. Administration of the drug usually 1-20 mg/kg (body weight) per day for adults improves the functional disturbances of multiple sclerosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 16, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 16, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 16, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.